Search		GO	Type Size:				Print This Page
Important Safety Information Full Prescribing Information

This information is intended for US healthcare professionals

Reimbursement and Billing

A profile of the coding systems and codes used for submitting claims for Vaprisol is provided below.

Coding System	Coding for Vaprisol
ICD-9-CM	276.1 – Hyposmolality and/or hyponatremia
	99.29 – Injection or infusion of other therapeutic or prophylactic substance
NDC	NDC 0469-1601-04 — 20 mg/4 mL 10s each NDC 0469-1602-11 — 100 mL in INTRAVIA Plastic Containers containing 20 mg in 5% dextrose
Revenue Codes	0250 – General pharmacy 0260 – Intravenous therapy

The coding, coverage, and payment information contained herein is gathered from various resources and is subject to change without notice. Astellas cannot guarantee success in obtaining third-party insurance payments. Third-party payment for medical products and services is affected by numerous factors, including whether a product is being used for an approved indication. It is always the provider’s responsibility to determine the appropriate healthcare setting and to submit appropriate codes, charges, and modifiers for services that are rendered, taking into account the approved indications for any product prescribed. Providers should contact third-party payers for specific information on their coding, coverage, and payment policies.

INTRAVIA is a registered trademark of Baxter International, Inc.

Stay Informed

Click here

Vaprisol Provides Proven Efficacy

Learn more about how Vaprisol raises serum [Na⁺] in a prompt but controlled fashion.

Click Here

Using Vaprisol in Your Patients

Learn how to use Vaprisol in a wide range of patients with dilutional hyponatremia.

Click here

Indication

Vaprisol is indicated for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients
Vaprisol is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events

Important Safety Information

Vaprisol is contraindicated in patients with hypovolemic hyponatremia. In addition, coadministration of Vaprisol with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, and indinavir, is contraindicated
Serum sodium, volume, and neurological status must be monitored frequently because Vaprisol potentially can cause overly rapid correction of sodium leading to serious sequelae
The use of Vaprisol in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering Vaprisol to these patients
The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day, respectively) which were also the most common type of adverse reaction leading to discontinuation of Vaprisol. Discontinuations from treatment due to infusion site reactions were more common among Vaprisol-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20 mg/day and 40 mg/day, respectively